Immuron (FRA:ANWA) Valuation Rank


FRA:ANWA Immuron Ltd FRA:ANWA
56 GF Score
Price €1.04
GF Value €5.48
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Immuron Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Immuron Valuation Rank Related Terms

FRA:ANWA
56GF Score
Immuron Ltd FRA:ANWA
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Immuron (FRA:ANWA) Overvalued in 2026?

Based on GuruFocus' analysis, Immuron stock appears to be undervalued. The current stock price of €1.04 is trading 81% below its estimated GF Value™ of €5.48. GuruFocus considers Immuron to be Possible Value Trap.

Key valuation signals for FRA:ANWA:

  • Valuation Rank:
  • GF Value™: €5.48 vs. price of €1.04 (81% below fair value)
  • GF Score™: 56/100 with 4 warning signs

No single metric tells the full story. See the FRA:ANWA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Immuron Business Description

Address 25-37, Chapman Street, Unit 10, Blackburn, Melbourne, VIC, AUS, 3130
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.
56GF Score

Get the complete analysis for FRA:ANWA

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.04
Price
€5.48
GF Value